Coblopasvir is a pan-genotypic inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A).1 It inhibits viral replication of the HCV genotypes 1a, -1b, -3a, -4a, -5a, and -6a in cellular assays and genotype 2a in a cell-free assay.
1.Rao, H., Song, G., Li, G., et al.Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosisJ. Viral. Hepat.27(1)45-51(2020)
















